Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07665450 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
MinorTrial sites expanded: 19 → 30 locationsEligibility criteria shortened, about 8 words · Secondary endpoints: details revised at 2 of 15 entries · Primary endpoints revised (2)Show 3 more changesShow less
Eligibility criteria shortened, about 8 words
Secondary endpoints: details revised at 2 of 15 entries
Primary endpoints revised (2)
NotableRecruitment openedLead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC · Trial sites expanded: 0 → 19 locations · Start date changed from estimate of Sep 22, 2026 to Sep 9, 2026 · 2 moreShow 5 more changesShow less
Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC
Trial sites expanded: 0 → 19 locations
Start date changed from estimate of Sep 22, 2026 to Sep 9, 2026
Eligibility criteria expanded, about 10 words
Secondary endpoints: details revised at 6 of 15 entries
MinorStart date: Sep 14, 2026 to Sep 22, 2026v3
MinorRe-verified, no change to tracked fieldsv2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and 12-month minimal residue disease (MRD)-negative complete response (CR) rate (percentage of participants in whom cancer cells are not detected) in participants with newly diagnosed multiple myeloma (NDMM; an initial stage of blood cancer that forms in a type of white blood cells \[WBCs\] called plasma cells) for whom stem cell transplant is not planned as initial therapy.